Proactive Investors - Run By Investors For Investors

Alliance Pharma sales rise as star brands perform

Sales were strong in Europe and international markets, especially China
skin
Scar tissue treatment Kelo-cote is booming

A strong performance from its portfolio of international brands boosted first-half sales at Alliance Pharma plc (LON:APH).

Turnover rose by 10% to £54.5m (2017: £49.4m) with scar tissue treatment Kelo-cote seeing sales rise by 77% while eye supplement Macushield was 22% ahead of a year ago.

READ: Alliance Pharma on target to meet market expectations after a solid first-half

Alliance recently boosted its ‘star’ brand portfolio with the acquisition of dandruff shampoo Nizoral and head lice treatment Vamousse, while pregnancy nausea aid Xonvea goes on sale this winter.

Reflecting the strength of the 'stars', sales were good in Europe and international markets, especially China, but smaller brands held back the UK

Alliance has decided to write-off its anti-malarial brands at a cost of £4.3mln after weak first-half sales, while there was also an impact from an increase in the regulated pharmacy product rebate.

Underlying profits rose by 2% to £12.1mln, but fell to £10.9mln from £16.9mln including one-off items. The interim dividend rose by 10% to 0,487p.

Peter Butterfield, chief executive, said the second half of the year has started well and based on trading performance in the year to date revenues and underlying profit before tax for the current financial year should be in line with expectations.

“Strategically, the priorities for the Group continue to be the delivery of organic growth, planning and starting to execute the integration of Nizoral and preparing for the UK launch of Xonvea in Q4 2018.

“We continue to evaluate bolt-on acquisitions with the objective of further driving our growth. Our ability to conclude such acquisitions is facilitated by our good cash generation and operational infrastructure.”

Shares were unchanged at 91p.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
man with erectile dysfunction
April 26 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use